Lymphadenopathy Evaluation and Management

Patient Assessment and History

• A thorough medical history, including recent infections or exposures, medication use, family history of autoimmune disease or malignancy, and travel history, is essential in the assessment of lymphadenopathy, considering associated symptoms, particularly B symptoms (fever, night sweats, weight loss >10% over 6 months), as recommended by the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 2

Diagnostic Workup

• A complete blood count with differential and peripheral smear is suggested as part of the initial diagnostic workup for lymphadenopathy, with specific testing, such as HIV, hepatitis B and C testing, considered based on clinical suspicion, as recommended by the National Comprehensive Cancer Network 3, 4, 1
• PET/CT is recommended for staging if malignancy is confirmed or when lymphoma is suspected, as outlined by the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 2

Imaging and Biopsy

• Ultrasound is the first-line imaging modality for initial evaluation, characterizing node size, internal architecture, and vascularity, and guiding FNA if needed, as recommended by the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 2
• The following table outlines the indications for different imaging modalities:

• Excisional biopsy is the gold standard for lymphoma diagnosis and is indicated when lymphadenopathy persists >4 weeks despite antibiotics, suspicious features for malignancy, or FNA is non-diagnostic, as recommended by the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the College of American Pathologists 1, 2, 5
• Fine-needle aspiration (FNA) is indicated for persistent lymphadenopathy (>3-4 weeks), nodes with suspicious features (hard, fixed, >1 cm), supraclavicular location (high risk for malignancy), or abnormal imaging findings, as recommended by the American College of Radiology 6, 7

Management and Referral

• Referral to a specialist is recommended if multiple enlarged nodes in different regions, persistent lymphadenopathy >4 weeks despite antibiotics, presence of B symptoms, abnormal complete blood count, or suspicion of lymphoma or leukemia, as outlined by the National Comprehensive Cancer Network and the American Society of Clinical Oncology 1, 2
• Specific referrals, such as ENT or surgical oncologist, should be considered based on the location and suspicion of underlying malignancy, with the American Society of Clinical Oncology recommending referral to an ear, nose, and throat (ENT) specialist or surgical oncologist for cervical, head and neck lymphadenopathy, posterior auricular lymphadenopathy with suspicious features, or need for excisional biopsy of cervical nodes 2
• Initial management of lymphadenopathy involves a single course of broad-spectrum antibiotics if signs of infection are present, with reassessment within 2 weeks of antibiotic treatment, and further workup, including imaging, if partial resolution or no resolution occurs, as recommended by medical guidelines 8

Pitfalls to Avoid

• Delaying biopsy in patients with persistent lymphadenopathy >4 weeks can lead to delayed diagnosis and treatment, and overlooking supraclavicular lymphadenopathy, which has the highest risk for malignancy, can lead to delayed diagnosis and treatment, as warned by the National Comprehensive Cancer Network 1
• Misinterpreting axillary lymphadenopathy following COVID-19 vaccination can lead to unnecessary testing and referral, and using corticosteroids before establishing a diagnosis can mask lymphoma and lead to delayed diagnosis, as cautioned by the National Comprehensive Cancer Network and the American College of Radiology 1, 9
• Relying solely on FNA when lymphoma is suspected can lead to inaccurate diagnosis, and excisional biopsy is preferred, as recommended by the National Comprehensive Cancer Network, the American Society of Clinical Oncology, and the College of American Pathologists 1, 2, 5